Progress in development of neutralizing monoclonal antibody ( McAb ) against MERS-CoV / 中华微生物学和免疫学杂志
Chinese Journal of Microbiology and Immunology
; (12): 696-702, 2017.
Article
em Zh
| WPRIM
| ID: wpr-657436
Biblioteca responsável:
WPRO
ABSTRACT
The rapid spread and outbreak of Middle East respiratory syndrome coronavirus ( MERS-CoV) in the regions of Middle East in 2012 have been a great concern for researchers worldwide. Thus, efficient preventative and therapeutic countermeasures are urgently needed. Clinical studies have con-firmed that high titers of neutralizing antibodies ( Abs) against MERS-CoV in patients during convalescence have protective potency, which indicates that neutralizing Abs are safe and effective for the treatment of MERS-CoV infection. Spike ( S) protein is a key structural protein that mediates MERS-CoV infection and currently a critical protein for studying MERS-CoV neutralizing monoclonal antibodies. This review summari-zes recent advances in identifying neutralizing McAbs against MERS-CoV through describing the structural characteristics of MERS-CoV S protein, different kinds of MERS-CoV vaccines and methods for mAbs screening. Furthermore, we propose the prospects for future research on MERS-CoV neutralizing McAbs ac-cording to the current research progress.
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Prognostic_studies
Idioma:
Zh
Revista:
Chinese Journal of Microbiology and Immunology
Ano de publicação:
2017
Tipo de documento:
Article